X0206 3 2019-06-19 0 0001714798 Prevail Therapeutics Inc. PRVL 0001778763 Kaplan Brett C/O PREVAIL THERAPEUTICS INC. 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 0 1 0 0 Chief Financial Officer Stock Option (Right to Buy) 2.81 2028-12-13 Common Stock 347004 D Stock Option (Right to Buy) 10.26 2029-04-24 Common Stock 64565 D 25% of the total number of shares underlying the option vested and became exercisable on November 12, 2019 and an additional 1/48th of the total number of shares underlying the option shall vest and become exercisable on the last date of each of the thirty-six (36) consecutive months thereafter subject, in all cases, to the Reporting Person providing continuous service with the Issuer on each such date. 25% of the total number of shares underlying the option shall vest and become exercisable on April 24, 2020 and an additional 1/48th of the total number of shares underlying the option shall vest and become exercisable on the same date of each of the thirty-six (36) consecutive months thereafter subject, in all cases, to the Reporting Person providing continuous service with the Issuer on each such date. Exhibit List - Exhibit 24- Power of Attorney No Table I Securities Beneficially Owned /s/ Alison Haggerty, Attorney-in-Fact 2019-06-19